Objective: This randomized, controlled clinical trial was conducted to assess the extrinsic stain reduction achieved by brushing with a whitening dentifrice and powered toothbrush, and to determine whether the addition of a whitening booster paste to this regimen would enhance its stain reducing effectiveness.
Methods: Sixty qualifying subjects were randomly assigned either to Regimen One, a whitening dentifrice (Arm & Hammer Truly Radiant [TR] toothpaste] and powered toothbrush (Arm & Hammer Truly Radiant [TR] Extra Whitening Spinbrush); Regimen Two, the dentifrice and powered toothbrush with the addition of a whitening booster; or Regimen Three, a negative control (Colgate Cavity Protection toothpaste and an ADA standard manual brush). They were instructed in the use of their assigned products and then brushed unsupervised at home for two minutes, twice daily, for 14 days. Extrinsic tooth stain was assessed at baseline and after two, five, and 14 days using a Modified Lobene Stain Index (MLSI) with Lobene inclusion criteria of ≥ 1.5.
Results: All three treatment groups had statistically significant (p < 0.0001) mean total MLSI reductions from baseline at each time point, in a time-dependent manner. Day 14 reductions were 22.2% for Colgate Cavity Protection, 29.1% for Regimen One, and 34.4% for Regimen Two. Reductions for Regimen One and Regimen Two were significantly greater compared to Regimen Three, the negative control, at each time period (p < 0.01), and those for Regimen Two were significantly greater compared to Regimen One on days 2 and 14 (p < 0.05) and directionally more effective on day 5 (p = 0.0673).
Conclusion: The combination of Truly Radiant toothpaste and Truly Radiant Spinbrush provides safe and effective stain removal that can be further enhanced by the addition of the whitening booster.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rho kinase inhibitor Y-27632 downregulates IL-1β expression in mice with experimental autoimmune myocarditis.
Sci Rep
April 2024
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Autoimmune myocarditis is the limited or diffuse inflammation of the myocardium due to dysfunctional cellular and humoral immunity mechanisms. We constructed mouse models of experimental autoimmune myocarditis (EAM) using peptide MyHC-α614-629. On the day after secondary immunization, the mice were intraperitoneally injected with Rho kinase (ROCK) inhibitor Y-27632.
View Article and Find Full Text PDFDomain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2.
Sci Transl Med
September 2023
Moderna, Inc., Cambridge, MA 02139, USA.
Article Synopsis
- The study explores new mRNA vaccine strategies to enhance effectiveness against COVID-19, focusing on specific protein domains of the virus instead of the full-length spike protein.
- The candidate vaccine mRNA-1283, combining the N-terminal domain and receptor binding domain, shows better antigen expression, stronger antibody responses, and improved stability compared to existing vaccines.
- In animal tests, mRNA-1283 elicits equal or greater immune protection against various COVID-19 variants, supporting its advancement to clinical trials for further evaluation.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Nat Med
January 2023
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Article Synopsis
- * Researchers tested two new bivalent vaccines (mRNA-1273.214 and mRNA-1273.222) in mice and found they produced stronger antibody responses against Omicron variants compared to the original vaccine.
- * Administering these bivalent vaccines as boosters significantly improved immune protection and reduced lung infection severity in mice, highlighting their potential effectiveness against circulating strains.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
bioRxiv
September 2022
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Article Synopsis
- The emergence of SARS-CoV-2 variants in the Omicron lineage has led to reduced vaccine effectiveness and ongoing virus transmission due to the spike protein's ability to evade antibodies.
- Researchers evaluated two bivalent vaccines that include mRNAs for spike proteins from both the original virus and recent variants (BA.1 or BA.4/5) and found they produced stronger immune responses in mice compared to existing monovalent vaccines.
- When used as a booster after initial vaccination, these bivalent vaccines not only generated a more robust antibody response but also provided greater protection against BA.5 infections and reduced inflammation in the lungs.
Article Synopsis
- Researchers developed a new mRNA vaccine, mRNA-1283, targeting specific spike protein domains of the virus responsible for COVID-19.
- This vaccine demonstrated enhanced antigen expression, antibody responses, and stability when stored in refrigerated conditions compared to the existing mRNA-1273 vaccine.
- In preclinical tests, mRNA-1283 provided similar or better immune protection against various COVID-19 variants in mice, indicating its potential for human clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!